Table of Contents
Overview
New York, NY – Nov 26, 2025 – Global Sequencing Market was valued at US$ 17.3 Billion in 2024 and is expected to grow at a CAGR of 21.4% from 2024 to 2034. In 2024, North America led the market, achieving over 49.3% share with a revenue of US$ 8.5 billion.
The structured sequence designed to communicate key information in a concise and authoritative manner. The document begins with a clear and compelling headline, which captures the core message and signals the significance of the announcement. A concise subheadline is often placed beneath it to provide additional context or highlight a secondary angle.
The dateline is then included to indicate the location and date of issuance. The opening paragraph provides the essential information, addressing the who, what, when, where, and why in a direct manner. The growth potential, strategic relevance, or market impact is usually introduced here to establish news value.
The second paragraph expands on background details. Context about the company, product, event, or initiative is presented to give depth. Supporting data, market trends, or performance indicators are often incorporated to strengthen credibility.
A quote from a senior spokesperson or executive follows. This section introduces a human voice and reinforces the strategic importance of the announcement. Subsequent paragraphs may outline technical details, operational features, or implementation timelines. The narrative remains factual and neutral, avoiding promotional tone while highlighting measurable impact.
The release concludes with a boilerplate, a short standardized description of the organization. Contact information for media inquiries is placed at the end to facilitate follow-up. This sequence ensures clarity, professional consistency, and effective communication for journalists and stakeholders.
Key Takeaways
- The global sequencing market reached a valuation of USD 17.3 billion in 2024 and is projected to expand to USD 37.0 billion by 2034, reflecting a 21.4% CAGR.
- In 2024, the consumables segment dominated the market, accounting for 49.2% of total revenue.
- The oncology segment emerged as the leading application area, representing 37.4% of the overall revenue share.
- The biotechnology and pharmaceutical companies segment held the highest share among end users, contributing 39.2% of global revenue.
- North America retained its dominant position with more than 49.3% of the global market share.
Regional Analysis
The North America sequencing market is registering strong growth, supported by active participation from research institutions, pharmaceutical manufacturers, and healthcare organizations. Genomics has become central to disease investigation and drug discovery, as genetic expression is recognized to play a critical role in human health outcomes. The region’s continued emphasis on genomic advancement is demonstrated through multiple collaborative initiatives designed to enhance the use of sequencing technologies in medical innovation.
One significant example is the partnership announced in January 2022 between Illumina, Inc. and Nashville Biosciences, LLC, a subsidiary of Vanderbilt University Medical Center. This collaboration is focused on applying genomic insights to drug development and establishing a large-scale clinical genomic resource.
The U.S. sequencing market is projected to observe substantial expansion over the assessment period, driven primarily by the increasing prevalence of cancer. As reported by the American Cancer Society, an estimated 611,720 cancer-related deaths and more than 2 million new cancer cases are expected in 2024.
Use Cases
- Outbreak Investigation and Pathogen Tracking: Next-generation sequencing has been implemented in public health laboratories to support rapid pathogen identification and variant monitoring. Under the CDC’s Advanced Molecular Detection program, sixty-four laboratories received sequencing and analytics support, strengthening outbreak response capacity and advancing genomic epidemiology capabilities.
- Rare Disease Diagnosis via Long-Read Sequencing: Long-read whole-genome sequencing has been utilized to diagnose rare genetic disorders with improved accuracy. A clinical study reported a 41.67% diagnostic yield among evaluable patients using 46–64× coverage, demonstrating the effectiveness of high-fidelity long-read platforms in precision medicine applications.
- Population-Scale Gene Panel Screening: Large-scale genomic screening initiatives have demonstrated high sequencing success rates, with 99.6% participant completion. A targeted gene panel identified a 3.7% screen-positive rate, supporting early detection of hereditary conditions and informing broad public-health planning and intervention strategies.
- Enhancing Regional Surveillance in Low-Resource Settings: Pathogen genomics adoption is expanding across low-resource regions to strengthen routine outbreak surveillance. The establishment of the Fiji Pathogen Genomics Laboratory illustrates rising regional capacity, enabling improved detection, monitoring, and control of infectious threats in the South Pacific and Southeast Asia.
Frequently Asked Questions on Sequencing
- How does DNA sequencing work?
DNA sequencing works by fragmenting genetic material and reading nucleotide arrangements through chemical, optical, or electrical detection systems. The results are analyzed using computational tools, allowing precise interpretation of genetic variations that influence biological processes, disease risks, and therapeutic responses. - What are the main types of sequencing technologies?
The principal sequencing technologies include Sanger sequencing, next-generation sequencing, and third-generation long-read platforms. These systems differ in throughput, accuracy, speed, and cost, enabling applications ranging from targeted gene panels to whole-genome and transcriptome sequencing. - Why is sequencing important in healthcare?
Sequencing is important because it allows detection of genetic abnormalities, assessment of disease predisposition, and selection of patient-specific therapies. The capability improves diagnostic accuracy, supports preventive care, and enhances overall treatment outcomes in modern healthcare systems. - What is whole-genome sequencing?
Whole-genome sequencing involves decoding the complete DNA of an organism, covering all coding and non-coding regions. This method generates highly detailed information used for disease research, rare disorder diagnosis, and comprehensive genetic profiling. - What is whole-exome sequencing?
Whole-exome sequencing focuses on protein-coding regions of the genome, which contain most clinically relevant mutations. This approach is cost-effective and widely employed for rare disease diagnostics, gene discovery, and targeted clinical investigations. - What is the role of bioinformatics in sequencing?
Bioinformatics is essential for managing, processing, and interpreting large sequencing datasets. Advanced algorithms and analytical tools convert raw reads into meaningful insights, enabling mutation detection, genome assembly, and clinical decision-support applications. - Which regions dominate the sequencing market?
North America leads the sequencing market due to advanced infrastructure, strong research funding, and high clinical adoption. Europe follows closely, while Asia-Pacific demonstrates the fastest growth driven by government programs and expanding healthcare modernization. - Who are the major players in the sequencing market?
Major companies include Illumina, Thermo Fisher Scientific, Pacific Biosciences, Oxford Nanopore Technologies, and BGI. These firms supply high-throughput instruments, consumables, and informatics solutions that support clinical diagnostics and large-scale genomic research.
Conclusion
The sequencing market is positioned for sustained expansion, supported by strong demand across clinical, research, and public-health applications. Growth has been driven by rising cancer incidence, rapid adoption of next-generation technologies, and expanding genomic initiatives in both developed and emerging regions.
North America continues to lead due to advanced infrastructure and high investment in precision medicine, while global collaborations are enhancing technological capabilities. Increasing use cases in rare disease diagnosis, pathogen surveillance, and population-scale screening further reinforce the market’s strategic relevance. Overall, sequencing is expected to remain a foundational component of modern healthcare and biomedical innovation.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
